Spyre Therapeutics, Inc.

NasdaqGS:SYRE Stock Report

Market Cap: US$1.6b

Spyre Therapeutics Management

Management criteria checks 0/4

Spyre Therapeutics' CEO is Cameron Turtle, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is $16.17M, comprised of 1.7% salary and 98.3% bonuses, including company stock and options. directly owns 1.45% of the company’s shares, worth $23.45M. The average tenure of the management team and the board of directors is 1.1 years and 1.4 years respectively.

Key information

Cameron Turtle

Chief executive officer

US$16.2m

Total compensation

CEO salary percentage1.7%
CEO tenure1.1yrs
CEO ownership1.5%
Management average tenure1.1yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09
Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

CEO Compensation Analysis

How has Cameron Turtle's remuneration changed compared to Spyre Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$215m

Jun 30 2024n/an/a

-US$186m

Mar 31 2024n/an/a

-US$364m

Dec 31 2023US$16mUS$273k

-US$339m

Compensation vs Market: Cameron's total compensation ($USD16.17M) is above average for companies of similar size in the US market ($USD5.38M).

Compensation vs Earnings: Insufficient data to compare Cameron's compensation with company performance.


CEO

Cameron Turtle (34 yo)

1.1yrs

Tenure

US$16,174,660

Compensation

Dr. Cameron Turtle, D.Phil, Ph D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre...


Leadership Team

NamePositionTenureCompensationOwnership
Cameron Turtle
CEO & Director1.1yrsUS$16.17m1.45%
$ 23.4m
Scott Burrows
Chief Financial Officer1.2yrsUS$7.55m0.030%
$ 477.4k
Heidy King-Jones
Chief Legal Officer & Corporate Secretary1.2yrsUS$6.93m0%
$ 0
Janet Gunzner-Toste
Senior Vice President of Operationsno datano datano data
Brian Connolly
Chief Technical Officerless than a yearno datano data
Eric McIntyre
Vice President of Finance & Investor Relationsno datano datano data
James Myers
Vice President of Quality & Complianceno datano datano data
Kelly Boothe
Senior Director of Corporate Communications & Investor Relationsno datano datano data
Justin LaFountaine
Senior Vice President of Corporate Developmentno datano datano data
Melissa Cooper
Senior Vice President of Peopleno datano datano data
James Kastenmayer
Consultant1.5yrsUS$865.79kno data
Joshua Friedman
Senior Vice President of Clinical Developmentless than a yearno datano data

1.1yrs

Average Tenure

44yo

Average Age

Experienced Management: SYRE's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Cameron Turtle
CEO & Directorless than a yearUS$16.17m1.45%
$ 23.4m
Daniel Von Hoff
Member of Scientific Advisory Board8.2yrsno datano data
Matthew Vander Heiden
Member of Scientific Advisory Board8.2yrsno datano data
Keith Flaherty
Member of Scientific Advisory Board8.2yrsno datano data
Jeffrey Albers
Independent Chairman of the Boardless than a yearUS$433.57k0.053%
$ 858.9k
Arthur Frankel
Member of Scientific Advisory Board8.2yrsno datano data
Wayne Klohs
Member of Scientific Advisory Board8.2yrsno datano data
Tomas Kiselak
Independent Director1.4yrsUS$658.43k0.79%
$ 12.7m
Mark McKenna
Independent Directorless than a yearno data0%
$ 0
Laurie Stelzer
Independent Directorless than a yearUS$434.38k0%
$ 0
Michael Henderson
Independent Director1.4yrsUS$660.78k0%
$ 0
Peter Harwin
Independent Director1.4yrsUS$661.28k0.79%
$ 12.7m

1.4yrs

Average Tenure

44yo

Average Age

Experienced Board: SYRE's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.